NewsMarkets

Health

Retatrutide Trial Shows Up to 25% Weight Loss in Obesity Drug Study

The experimental triple-hormone drug Retatrutide achieved up to 25 percent weight loss in its phase 3 clinical trial, marking a new benchmark for obesity treatments.

2 publishers · 2 articles · first seen 29 Sept 2026 · updated 2h ago

Markets on this story

  • Kalshi Before Jan 1, 2027 7% +4 $65 24hends 1 Jan 2027

    Does the market have this right?

    Wrong market?

How the odds moved · Before Jan 1, 2027
0%50%100%7%28 Sept, 22:15 UTCnowArs Technica: Most powerful obesity drug yet: People lost up to 25% of weight in trial · 29 Sept, 22:30 UTCScientific American: Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs · 29 Sept, 22:01 UTC

Each tick is a source publishing on this story

Price data
TimeChance of yes
now7%
29 Sept, 22:38 UTC7%
28 Sept, 22:15 UTC3%

Your call. How does this end?

Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls

Email me when the odds move

We email a link to confirm first. At most one alert email every six hours; unsubscribe in one click. Privacy

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Most powerful obesity drug yet: People lost up to 25% of weight in trial Ars Technica ·
  2. Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs Scientific American

In this story

  • Retatrutide